tooluniverse-clinical-trial-design

Clinical trial feasibility is assessed by sizing patient populations, estimating biomarker prevalence, selecting evidence-grade endpoints, and mapping regulatory pathways. This process generates a defensible feasibility score with risk mitigations for Phase 1/2 and basket trials.

Yes, enrollment projections and endpoint strategy guidance are core features. It supports complex basket and umbrella trial designs across oncology indications, integrating population sizing and risk mitigation planning.

Regulatory pathway assessment and biomarker prevalence estimation use documented sources including OpenTargets, ClinVar, gnomAD, FDA Orange Book, and clinical trial registries to ensure evidence-grade inputs and outputs.

Yes, feasibility profiling explicitly includes risk mitigation planning. It produces a defensible feasibility score for Phase 1/2 biomarker-driven trials while documenting risk-management strategies and regulatory pathways.

The best way to size patient populations is analyzing biomarker prevalence and indication-specific data using ToolUniverse. This yields defensible feasibility scores, enrollment projections, and evidence-grade endpoints.

This approach is specifically applied across oncology indications for Phase 1/2 and biomarker-driven studies. Feasibility profiling, endpoint selection, and enrollment projections are optimized for oncology basket and umbrella designs.